News
J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...
Investor's Business Daily on MSN2d
AnaptysBio Earns RS Rating Upgrade
In a welcome move, AnaptysBioANAB saw its Relative Strength Rating rise from 61 to 74 on Thursday.Please watch the video at ...
AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...
SAN DIEGO - AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stagebiotechnology company, announced positive results from its GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab, a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback